收费全文 | 26489篇 |
免费 | 1387篇 |
国内免费 | 161篇 |
医药卫生 | 28037篇 |
2023年 | 194篇 |
2022年 | 191篇 |
2021年 | 859篇 |
2020年 | 506篇 |
2019年 | 726篇 |
2018年 | 943篇 |
2017年 | 627篇 |
2016年 | 704篇 |
2015年 | 808篇 |
2014年 | 1060篇 |
2013年 | 1297篇 |
2012年 | 2079篇 |
2011年 | 2033篇 |
2010年 | 1238篇 |
2009年 | 1059篇 |
2008年 | 1745篇 |
2007年 | 1711篇 |
2006年 | 1656篇 |
2005年 | 1524篇 |
2004年 | 1357篇 |
2003年 | 1230篇 |
2002年 | 1218篇 |
2001年 | 245篇 |
2000年 | 217篇 |
1999年 | 239篇 |
1998年 | 217篇 |
1997年 | 139篇 |
1996年 | 131篇 |
1995年 | 161篇 |
1994年 | 132篇 |
1993年 | 121篇 |
1992年 | 138篇 |
1991年 | 105篇 |
1990年 | 137篇 |
1989年 | 111篇 |
1988年 | 125篇 |
1987年 | 80篇 |
1986年 | 109篇 |
1985年 | 91篇 |
1984年 | 90篇 |
1983年 | 79篇 |
1982年 | 74篇 |
1981年 | 50篇 |
1980年 | 51篇 |
1979年 | 41篇 |
1978年 | 48篇 |
1977年 | 29篇 |
1973年 | 31篇 |
1972年 | 40篇 |
1971年 | 28篇 |
Areas covered: This review first focuses on the clinical trials evaluating the efficacy and tolerability of nab-paclitaxel in NSCLC at different settings. The approval of nab-paclitaxel in combination with carboplatin at the front-line setting for advanced NSCLC was based on the key phase III study, which showed that nab-paclitaxel/carboplatin was associated with superior overall response rate and favorable toxicity profile compared to sb-paclitaxel/carboplatin. The review also addresses the nab-paclitaxel pharmacology, other combinations (e.g. immunotherapy with PD-1/PD-L1 inhibitors), potential biomarkers (e.g. caveolin-1), and special subgroups (e.g. the elderly, squamous histology).
Expert opinion: Existing data has established the role of nab-paclitaxel in the management of advanced NSCLC. Emerging evidence, such as preliminary results from Keynote-407 and IMpower 131 studies, indicates that novel combinations of nab-paclitaxel/carboplatin and PD-1/PD-L1 inhibitors could further improve clinical benefits with manageable toxicity. Nevertheless, in order to better position nab-paclitaxel and to improve patient selection, future studies are warranted to further understand its mechanism of action, predictive biomarkers, and potential synergism with other agents. 相似文献
Areas covered: We discuss the potential mechanism supporting the contribution of visfatin to RA and the association between RA and obesity. We discuss the repurposing of cancer-tested drugs to inhibit visfatin in the context of RA. Additionally, we address the possibility of combining these drugs with current RA therapy. Finally, we explore the future of visfatin as an RA biomarker or therapeutic target.
Expert opinion: Inhibition of visfatin has become an interesting therapeutic approach for RA pathology. Such a feat has already been attained in oncology using small molecule inhibitors, which suggest that a similar course of action would be worth pursuing in the RA context. Visfatin will become an important biomarker and therapeutic target for RA. 相似文献